Astaxanthin

What is Astaxanthin?

Astaxanthin is a naturally occurring xanthophyll carotenoid found in marine and aquatic organisms. It is structurally related to carotenoids such as beta-carotene and lutein, but its oxygen-containing groups and long conjugated chain give it distinctive membrane-associated properties. This amphipathic structure allows astaxanthin to interact with different regions of lipid membranes and with reactive species generated within those membranes. (Si & Zhu, 2022; Zhu et al., 2025)

Natural astaxanthin is synthesised by microalgae, with Haematococcus pluvialis being an important commercial source. It then accumulates through the aquatic food chain and is found in foods including salmon, trout, shrimp and lobster. Unlike beta-carotene, astaxanthin is generally classified as a non-provitamin A carotenoid and is not considered a significant dietary precursor of vitamin A. (Si & Zhu, 2022; Zhu et al., 2025)

Following oral intake, astaxanthin is absorbed through the intestine and has been detected in circulating plasma and erythrocytes. Human research has demonstrated antioxidant activity at the erythrocyte membrane, while preclinical evidence indicates that astaxanthin can cross the blood-brain barrier. These properties provide a biological basis for research into systemic oxidative stress, mitochondrial function, skin photoprotection and neurological outcomes. (Nakagawa et al., 2011; Si & Zhu, 2022)

Astaxanthin is particularly relevant to healthy ageing research because oxidative stress and mitochondrial dysfunction are closely linked to age-associated cellular damage. Experimental and human studies have therefore examined whether astaxanthin can reduce oxidative injury, reinforce endogenous antioxidant responses and influence downstream stress-signalling pathways. (Kim & Kim, 2018; Zhu et al., 2025)

Longevita's astaxanthin is derived from Haematococcus pluvialis, the source used in many studies of naturally derived astaxanthin. For broader context on how antioxidant and mitochondrial pathways sit within Longevita's healthy ageing science, explore the Longevita ingredient library.

Below, we review the mechanisms that have made astaxanthin a focus of healthy-ageing research, followed by the human evidence for skin, cognitive, inflammatory and cardiovascular-related outcomes.

Why Astaxanthin Matters for Healthy Ageing

Oxidative stress develops when the generation of reactive oxygen species exceeds the capacity of antioxidant and repair systems to control them. Over time, this can contribute to lipid peroxidation, mitochondrial dysfunction, damage to proteins and DNA, and disruption of cellular signalling. Astaxanthin's potential relevance to healthy ageing is therefore linked primarily to its antioxidant activity at biological membranes and its effects on mitochondrial and cellular stress-response pathways. (Kim & Kim, 2018; Zhu et al., 2025)

The distinction between mechanism and clinical outcome is important. Human research has investigated astaxanthin in areas relevant to ageing biology, including UV-related skin changes, cognitive performance, and oxidative or inflammatory biomarkers. However, the available trials are generally modest in size and vary in population, dose, duration and endpoint. The evidence is therefore most useful when interpreted outcome by outcome rather than as proof of a general anti-ageing effect. (Ito et al., 2018; Katagiri et al., 2012; Utomo et al., 2024)

Systemic Healthy-Ageing Effects of Astaxanthin

1. Mitochondrial Function and Oxidative Stress

Mitochondria are both a major source of reactive oxygen species and a key target of oxidative injury. In experimental models, astaxanthin has been shown to reduce lipid peroxidation and oxidative damage to mitochondrial membranes, preserve mitochondrial membrane potential and help maintain mitochondrial function under oxidative stress. (Kim & Kim, 2018; Zhu et al., 2025)

Its molecular structure may be particularly relevant here. Because astaxanthin can span and associate with lipid membranes, it can interact with reactive species in the membrane environment rather than acting only within a single aqueous or lipid compartment. This membrane-level activity is one reason astaxanthin has been studied as a lipid-phase antioxidant in cells and circulating erythrocytes. (Nakagawa et al., 2011; Si & Zhu, 2022)

Experimental research also suggests that astaxanthin can be transported to mitochondria and influence mitochondrial apoptotic processes. In neuronal cell models exposed to oxidative stress, astaxanthin reduced excessive mitophagy and apoptosis while preserving Akt/mTOR signalling. These findings help explain a possible cellular mechanism, although this particular pathway has primarily been demonstrated experimentally rather than in human clinical studies. (Yan et al., 2024; Zhu et al., 2025)

For a related Longevita ingredient focused on mitochondrial energy and oxidative protection, see the Coenzyme Q10 ingredient page.

2. Endogenous Antioxidant Defence and Nrf2/ARE Signalling

Astaxanthin is not studied only as a direct free-radical scavenger. It has also been investigated for its ability to influence endogenous antioxidant defence systems, particularly the Nrf2/antioxidant response element (ARE) pathway. Activation of this pathway can increase the expression of antioxidant and detoxification enzymes that help cells respond to oxidative stress. (Zhu et al., 2025)

In a 2026 in-vitro study using human periodontal ligament stem cells, astaxanthin activated Nrf2/ARE signalling and was associated with lower intracellular and mitochondrial reactive oxygen species alongside preservation of mitochondrial membrane potential. Earlier work in human granulosa cells similarly reported protection against oxidative stress through Nrf2/ARE activation and downstream phase II enzymes. (Chi et al., 2026; Eslami et al., 2021)

These mechanistic data support the idea that astaxanthin may act on more than one layer of oxidative defence: directly at lipid membranes and indirectly through cellular antioxidant-response pathways. The clinical relevance of these signalling effects still depends on the population and outcome being studied. (Zhu et al., 2025)

3. Inflammation and Cellular Stress Signalling

Oxidative stress and inflammatory signalling are closely interconnected, which is why several astaxanthin trials have measured both types of biomarkers. In a randomised, triple-blind, placebo-controlled trial involving 50 women with endometriosis undergoing assisted reproduction, 12 weeks of 6 mg/day astaxanthin increased serum total antioxidant capacity and superoxide dismutase and reduced malondialdehyde and selected inflammatory cytokines. (Rostami et al., 2023)

A separate randomised, double-blind trial in 56 women with polycystic ovary syndrome found that eight weeks of 12 mg/day astaxanthin was associated with favourable changes in inflammatory markers and expression of genes related to endoplasmic-reticulum stress and apoptosis in peripheral blood mononuclear cells. (Jabarpour et al., 2024)

These are meaningful biomarker-level findings, but they come from specific clinical populations. They should not be generalised into a universal anti-inflammatory effect in all adults. Instead, they add human evidence to the broader experimental literature showing that astaxanthin can influence oxidative, inflammatory and cellular stress pathways. (Rostami et al., 2023; Jabarpour et al., 2024; Zhu et al., 2025)

4. Cognitive and Neurological Function

The brain is highly metabolically active and sensitive to oxidative and mitochondrial stress, making astaxanthin a compound of interest in cognitive-ageing research. Preclinical evidence indicates that astaxanthin can cross the blood-brain barrier, while experimental neuronal models suggest effects on oxidative injury, mitophagy and apoptosis. (Si & Zhu, 2022; Yan et al., 2024)

Human evidence is still limited but includes randomised trials. In a double-blind, placebo-controlled study of 96 healthy middle-aged and older adults with age-related forgetfulness, 12 weeks of astaxanthin-rich Haematococcus pluvialis extract at 6 or 12 mg/day was associated with improvements in selected cognitive test measures. The authors also noted that the sample size was too small to establish a significant difference in overall cognitive function between treatment and placebo groups. (Katagiri et al., 2012)

A 2024 systematic review identified four randomised controlled trials involving 207 middle-aged and older adults and reported generally positive findings across the included cognitive studies. At the same time, the small number of trials, varied cognitive measures and limited sample sizes mean that larger, better-powered studies are still required before firm conclusions can be drawn. (Utomo et al., 2024)

5. Cardiovascular Health and Lipid-Related Biomarkers

Astaxanthin has also been investigated in relation to cardiovascular biology because oxidative stress, lipid peroxidation, inflammation and mitochondrial dysfunction all influence vascular and cardiac health. Experimental research suggests that astaxanthin can affect LDL oxidation, inflammatory signalling and mitochondrial oxidative damage in cardiovascular models. (Fan et al., 2017; Daoud, 2025; Zhu et al., 2025)

For example, experimental work has shown protection against homocysteine-induced cardiotoxicity through reductions in mitochondrial dysfunction and oxidative damage. Reviews of the broader literature describe potential effects on selected lipid and oxidative-stress markers, but the strength of human clinical evidence varies by outcome and population. (Fan et al., 2017; Daoud, 2025)

For this reason, the cardiovascular evidence is best described as developing rather than definitive. Astaxanthin has biologically plausible mechanisms and encouraging biomarker findings, but larger outcome-focused human trials would be needed to determine the consistency and clinical significance of these effects. (Zhu et al., 2025; Daoud, 2025)

Astaxanthin and Skin Photoprotection

Skin is continuously exposed to ultraviolet radiation, which can increase reactive oxygen species, weaken barrier function and contribute to visible photodamage. Astaxanthin has been studied for skin health because its membrane-associated antioxidant activity may help limit oxidative damage triggered by UV exposure. (Kim & Kim, 2018; Zhu et al., 2025)

One of the clearest human trials was a 10-week randomised, double-blind, placebo-controlled study involving 23 healthy Japanese adults. Supplementation with 4 mg/day astaxanthin increased the minimal erythema dose, meaning a greater UV exposure was required to produce visible redness, and reduced UV-induced loss of skin moisture compared with placebo. (Ito et al., 2018)

This trial is relevant because it measured the skin's response to a controlled UV challenge rather than relying only on self-reported appearance. It provides human evidence that oral astaxanthin can influence selected photoprotection and moisture-retention outcomes, although the study was small and does not establish protection equivalent to sunscreen or other established photoprotective measures. (Ito et al., 2018)

Across the available clinical literature, skin-related outcomes have typically been assessed after roughly nine to ten weeks, while other biomarker and cognitive studies have used periods of about eight to twelve weeks. These study durations describe when researchers measured outcomes and should not be interpreted as a guaranteed time to experience a benefit. (Ito et al., 2018; Rostami et al., 2023; Jabarpour et al., 2024; Katagiri et al., 2012)

Clinical Evidence, Dose and Safety

Taken together, the current human literature suggests that astaxanthin has measurable biological activity, particularly in relation to oxidative stress and UV-induced skin responses, with additional research in cognition and inflammatory biomarkers. However, the trials differ substantially in population, dose, duration and endpoint, which makes direct comparison difficult and limits broad claims about clinical effect size. (Ito et al., 2018; Katagiri et al., 2012; Rostami et al., 2023; Jabarpour et al., 2024; Utomo et al., 2024)

Safety assessments and clinical studies generally report good tolerability at the doses studied. EFSA's 2020 assessment concluded that combined exposure from the background diet plus up to 8 mg/day from food supplements was safe for adults. The assessment used an acceptable daily intake of 0.2 mg/kg body weight per day; for a 70 kg adult, this corresponds to approximately 14 mg/day. The 8 mg/day figure refers specifically to the supplement exposure evaluated by EFSA and should not be presented as a general therapeutic dose. (EFSA NDA Panel, 2020)

Clinical research has also evaluated natural astaxanthin at doses of up to 12 mg/day. In the Katagiri cognitive trial, no adverse effects were observed during 12 weeks at the studied doses, while a dedicated safety review covering 87 human studies reported no identified safety concerns associated with natural astaxanthin supplementation, including 35 studies using doses of at least 12 mg/day. (Katagiri et al., 2012; Brendler & Williamson, 2019)

Astaxanthin is lipid-soluble, and dietary fat can improve its intestinal absorption and overall bioavailability. Taking it with a meal containing fat may therefore improve absorption compared with taking it on an empty stomach. (Zhu et al., 2025)

Current human data support good tolerability across the doses and durations studied, but long-term evidence extending well beyond several months is more limited than short-term clinical evidence. Human interaction data are also limited. People who are pregnant or breastfeeding, taking prescription medication, or managing a diagnosed medical condition should discuss supplementation with a healthcare professional. (EFSA NDA Panel, 2020; Brendler & Williamson, 2019)